Skip to content
Screener

Zymeworks ZYME Preferred Stock, Shares Authorized

Preferred Stock, Shares Authorized at other companies

Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$10M0.0%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$5M0.0%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$10M0.0%

Other financials

Income statement

See full
Revenue$4.6M-90.6%
Operating income-$42.2M-6,158%
Net income-$45.0M-2,043%
EPS (diluted)-$0.62-2,167%

Balance sheet

See full
Cash & equivalents$179.4M+82.6%
Total debt$16.0M-14.3%
Total equity$80.4M-76.0%
Total assets$397.0M-2.8%

Cash flow

See full
Operating cash flow-$31.9M-365%
CapEx$216.0K+1,250%
Free cash flow-$31.9M-376%

Valuation

See full
Market cap$1.71B+82.0%
Enterprise value$1.55B+79.8%
P/S46.2×+38.5×

Profitability

See full
Operating margin-419%-518pp
Net margin-404%-489pp
FCF margin-324.7%-366pp

Returns & leverage

See full
Return on equity-72.3%-117pp
Debt / equity0.2×+0.1×
Current ratio6.3×-1.4×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The source filing: Zymeworks’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001937653-26-000047
AssetsJune 30,2026 / (unaudited)December 31,2025
Total liabilities316,59578,026
Stockholders’ equity:
Common stock, $0.00001 par value; 900,000,000 authorized shares at June 30, 2026 and December 31, 2025, respectively; 71,412,072 and 74,638,413 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively1,133,9591,105,176
Preferred shares, $0.00001 par value; 100,000,000 authorized shares of preferred stock, out of which, one share of preferred stock is a share of Special Voting Preferred Stock and outstanding as of June 30, 2026 and December 31, 2025
Exchangeable shares, no par value, 550,000 and 553,184 issued and outstanding shares at June 30, 2026 and December 31, 2025, respectively7,8927,938
Additional paid-in capital116,450114,626
Accumulated other comprehensive loss(6,694)(6,079)
Accumulated deficit(1,171,238)(953,160)

Item 1. Financial Statements

FAQ

What is Zymeworks's preferred stock, shares authorized?
Zymeworks (ZYME) reported preferred stock, shares authorized of $100M in Q2 2026.
How has Zymeworks's preferred stock, shares authorized changed year-over-year?
Zymeworks's preferred stock, shares authorized decreased by 0.0% year-over-year, from $100M to $100M.
What is the long-term trend for Zymeworks's preferred stock, shares authorized?
Over 3 years (2022 to 2025), Zymeworks's preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from $100M to $100M.
What does preferred stock, shares authorized mean?
Preferred Stock, Shares Authorized

Ask your AI about Zymeworks's preferred stock, shares authorized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude